Crossmark

Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

Crossref DOI link: https://doi.org/10.1007/s00520-023-07791-7

Published Online: 2023-05-10

Published Print: 2023-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karaboyun, Kubilay https://orcid.org/0000-0002-1783-8075
Cavdar, Eyyup https://orcid.org/0000-0001-5885-3047
Irıagac, Yakup https://orcid.org/0000-0001-7411-1705
Celebı, Abdussamet https://orcid.org/0000-0002-6922-1018
Kapagan, Tanju https://orcid.org/0000-0001-9381-1934
Gulturk, Ilkay https://orcid.org/0000-0003-1998-3150
Demır, Ozden https://orcid.org/0000-0002-7705-7027
Avcı, Okan https://orcid.org/0000-0003-3773-6620
Seber, Erdogan Selcuk https://orcid.org/0000-0001-9081-2405
License Information

Text and Data Mining valid from 2023-05-10

Version of Record valid from 2023-05-10
More Information

Article History

Received: 10 November 2022

Accepted: 1 May 2023

First Online: 10 May 2023

Declarations

:

: The present study was performed in line with the principles of the Declaration of Helsinki. The Tekirdag Namik Kemal University Ethics Committee granted formal approval to this study (approval no: 2021.138.05.11 on May 27th, 2021).

: Informed consent was obtained from all individual participants included in the study.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below